Depressive Disorders, Fabry Disease

Depressive Disorders

1.Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39(1): 43-53, 1/2005.

2.Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Dernyttenaere K. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: A Randomized controlled trial. Journal of Clinical Psychiatry 68(11): 1707-1716, 11/2007.

3.Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. Clin Ther 26(8):

1249-1260, 8/2004.

4.Davison SN, Jhangri GS. The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients. J Pain Symptom Manage 30(5): 465- 473, 11/2005.

5.Friedberg F, Quick J. Alexithymia in chronic fatigue syndrome: associations with momentary, recall, and retrospective measures of somatic complaints and emotions. Psychosom Med 69(1): 54-60, 1/2007.

6.Hartman JM, Berger A, Baker K, Bolle J, Handel D, Mannes A, Pereira D, St GD, Sonbolian N, Ronsaville D, Torvik S, Calis KA, Phillips TM, Cizza G. Quality of life and pain in premenopausal women with major depressive disorder: The POWER Study. Health Qual Life Outcomes 4(1): 2, 1/2006.

7.O'Mahony S, Goulet J, Kornblith A, Abbatiello G, Clarke B, Kless-Siegel S, Breitbart W, Payne R. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. J Pain Symptom Manage 2005;29:446- 457.Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 22(2):

173-181, 2/2006.

8.Poleshuck EL, Giles DE, Tu X. Pain and depressive symptoms among financially disadvantaged women's health patients. J Womens Health (Larchmt ) 15(2): 182-193, 3/2006.

9.Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric History and Psychologic Adjustment as Risk Factors for Aberrant Drug-related Behavior Among Patients With Chronic Pain. Clin J Pain 23(4): 307-315, 5/2007.

10.Williams LS, Jones WJ, Shen J, Robinson RL, Kroenke K. Outcomes of newly referred neurology outpatients with depression and pain. Neurology 63(4): 674-677, 8/2004.

Fabry Disease

1.Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34(12): 838-844, 12/2004.

2.Cleeland CS. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 91(439): 43-47, 2002.

3.Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43(4):

347-352, 4/2006.

4.Hoffmann B, Garcia de LA, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 42(3): 247-252, 3/2005.

5.Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96(1): 122-127, 1/2007.

6.Ries M, Mengel E, Kutschke G, Kim KS, Birklein F, Krummenauer F, Beck M. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 26(4): 413-414, 2003.